title: Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease.
abstract: Encapsulated human mesenchymal stem cells(MSC) are studied in a double transgenic mouse model of Alzheimer's disease (AD) after intraventricular implantation at 3 months of age. Abeta 40/42 deposition, and glial (GFAP) and microglial (CD11b) immunoreactivity were investigated 2 months after transplantation of either native MSC or MSC transfected with glucagon-like peptide-1 (GLP-1). CD11b immunostaining in the frontal lobes was significantly decreased in the GLP-1 MSC group compared to the untreated controls. Also, the plaque associated GFAP immunoreactivity was only observed in one of four animals in the GLP-1 MSC group. Abeta 40 whole brain ELISA was decreased in the MSC group: 86.06±5.2 pg/ml (untreated control) vs. 78.67±11.2 pg/ml (GLP-1 MSC group) vs.70.9±11.1 pg/ml (MSC group, p<0.05). Intraventricular transplantation of native and GLP-1 transfected MSC has been shown effective. Decreased amyloid deposition or suppression of glial and microglial responses were observed. However, encapsulation of MSC may alter their biological activity.
authors.affiliation: Neurosurgery Foundation, Rhode Island Hospital/Warren Alpert Medical School, Brown University, Providence, RI, USA.
authors.forename: Petra M
authors.initials: PM
authors.lastname: Klinge
authors.forename: Kathrin
authors.initials: K
authors.lastname: Harmening
authors.forename: Miles C
authors.initials: MC
authors.lastname: Miller
authors.forename: Anna
authors.initials: A
authors.lastname: Heile
authors.forename: Christine
authors.initials: C
authors.lastname: Wallrapp
authors.forename: Peter
authors.initials: P
authors.lastname: Geigle
authors.forename: Thomas
authors.initials: T
authors.lastname: Brinker
mesh_terms: D000464:Alginates / Q000494:pharmacology; D000544:Alzheimer Disease / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000378:metabolism; D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology; D002214:Capsules; D002460:Cell Line; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy / Q000379:methods*; D052216:Glucagon-Like Peptide 1 / Q000235:genetics*; D020723:Glucuronic Acid / Q000494:pharmacology; D006603:Hexuronic Acids / Q000494:pharmacology; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells; D051379:Mice; D008822:Mice, Transgenic; D014162:Transfection
chemical_list: D000464:Alginates; D016229:Amyloid beta-Peptides; D001672:Biocompatible Materials; D002214:Capsules; D006603:Hexuronic Acids; D052216:Glucagon-Like Peptide 1; D020723:Glucuronic Acid